Press releases

April 26, 2022

Ambagon Therapeutics Appoints Gideon Bollag, Ph.D., to Scientific Advisory Board

January 6, 2022

Ambagon Therapeutics Launches with $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline

Media Contact

Rhiannon Jeselonis

In The News

Michael J. Fox Foundation for Parkinson's Research | April 8, 2023

Ambagon and academic collaborators awarded grant from the Michael J Fox Foundation to study 14-3-3:LRRK2 stabilizers as a neuroprotective therapy for Parkinson’s Disease.

BioCentury | January 5, 2023

2022 Class of Emerging Companies

BioSpace | January 4, 2023

Top Life Sciences Startups to Watch in 2023

BioCentury | February 1, 2022

Ambagon: creating molecular glues for disordered proteins